keyword
MENU ▼
Read by QxMD icon Read
search

Rabeprazole

keyword
https://www.readbyqxmd.com/read/28688035/metformin-accelerates-glycolytic-lactate-production-in-cultured-primary-cerebellar-granule-neurons
#1
Eva-Maria Blumrich, Ralf Dringen
Metformin is the most frequently used drug for the treatment of type-II diabetes. As metformin has been reported to cross the blood-brain barrier, brain cells will encounter this drug. To test whether metformin may affect the metabolism of neurons, we exposed cultured rat cerebellar granule neurons to metformin. Treatment with metformin caused a time- and concentration-dependent increase in glycolytic lactate release from viable neurons as demonstrated by the three-to fivefold increase in extracellular lactate concentration determined after exposure to metformin...
July 7, 2017: Neurochemical Research
https://www.readbyqxmd.com/read/28674348/randomized-trial-comparing-esomeprazole-and-rabeprazole-in-first-line-eradication-therapy-for-helicobacter-pylori-infection-based-on-the-serum-levels-of-pepsinogens
#2
Tadashi Shimoyama, Daisuke Chinda, Yoshihiko Sawada, Kazuo Komai, Hironobu Chiba, Yoshiharu Saito, Yoshio Sasaki, Masashi Matsuzaka, Shinsaku Fukuda
Objective CYP2C19 metabolic activity influences the efficacy of Helicobacter pylori eradication therapies comprising PPIs. Rabeprazole (RPZ) and esomeprazole (EPZ) are PPIs not extensively metabolized by CYP2C19. The aim of this study was to elucidate whether or not first-line triple therapies using RPZ or EPZ are equally effective in Japanese patients with different CYP2C19 genotypes. Methods Two-hundred patients infected with H. pylori were randomized to receive one of the following regimens: amoxicillin (750 mg), clarithromycin (200 mg), and either esomeprazole (20 mg) (EAC group) or rabeprazole (10 mg) (RAC group), twice a day for one week...
2017: Internal Medicine
https://www.readbyqxmd.com/read/28655978/early-effect-on-intragastric-ph-of-oral-administration-of-rabeprazole-with-mosapride-compared-with-rabeprazole-alone
#3
Hiroshi Iida, Megumi Kaai, Yumi Inoh, Kenji Kanoshima, Kanji Ohkuma, Takashi Nonaka, Koji Fujita, Tomonori Ida, Akihiko Kusakabe, Shin Maeda, Atsushi Nakajima, Masahiko Inamori
BACKGROUND: An ideal medication for acid-related diseases would offer prompt stopping of blood flow as well as efficient symptom resolution. The aim of this study was to investigate the gastric acid suppression potency of a single oral dose of rabeprazole alone, compared with administration of rabeprazole plus mosapride. METHODS: Twelve male volunteers, Helicobacter pylori (H. pylori)-negative, participated in this randomized, three-way crossover study. After a single oral administration of rabeprazole, rabeprazole with mosapride, or rabeprazole administered 1 h after mosapride, we monitored their intragastric pH constantly for 6 h...
2017: Annals of Gastroenterology: Quarterly Publication of the Hellenic Society of Gastroenterology
https://www.readbyqxmd.com/read/28644575/comparison-of-10-days-levofloxacin-bismuth-based-quadruple-therapy-and-levofloxacin-based-triple-therapy-for-helicobacter-pylori-therapy
#4
Tzung-Shiun Wu, Ping-I Hsu, Chao-Hung Kuo, Huang-Ming Hu, I-Chen Wu, Sophie S W Wang, Yen-Hsu Chen, Deng-Chyang Wu, Wei-Wen Su, Fu-Chen Kuo
BACKGROUND: This was a prospective study, the aid was to prove if levofloxacin plus Bismuth-based quadruple therapy was more effective than levofloxacin-based triple therapy after failure of first-line therapies. METHODS: We collected total of 67 patients, who was infected by H.pylori. Patients were enrolled and were randomly assigned to two groups; one was levofloxacin plus Bismuth-based quadruple therapy (RBAL group) (Rabeprazole 20 mg b.i.d., bismuth subcitrate 120 mg q...
June 23, 2017: Journal of Digestive Diseases
https://www.readbyqxmd.com/read/28588208/human-dimethylarginine-dimethylaminohydrolase-1-inhibition-by-proton-pump-inhibitors-and-the-cardiovascular-risk-marker-asymmetric-dimethylarginine-in-vitro-and-in-vivo-significance
#5
S Tommasi, D J Elliot, J A Hulin, B C Lewis, M McEvoy, A A Mangoni
Proton pump inhibitor (PPI)-induced inhibition of dimethylarginine dimethylaminohydrolase 1 (DDAH1), with consequent accumulation of the nitric oxide synthase inhibitor asymmetric dimethylarginine (ADMA), might explain the increased cardiovascular risk with PPI use. However, uncertainty exists regarding whether clinical PPI concentrations significantly inhibit DDAH1 under linear initial rate conditions, and whether PPI-induced DDAH1 inhibition significantly increases ADMA in humans. DDAH1 inhibition by esomeprazole, omeprazole, pantoprazole, lansoprazole and rabeprazole was determined by quantifying DDAH1-mediated L-citrulline formation in vitro...
June 6, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28577017/effect-of-cyp2c19-gene-polymorphisms-on-proton-pump-inhibitor-amoxicillin-and-levofloxacin-triple-therapy-for-eradication-of-helicobacter-pylori
#6
Yun-An Lin, Hong Wang, Zhu-Jun Gu, Wen-Jia Wang, Xiao-Yan Zeng, Yan-Lei Du, Song-Song Ying, Bo-Hua Zhang
BACKGROUND The effects of PPI are variable owing to the CYP2C19 polymorphisms. However, whether the polymorphisms could affect the Hp eradication efficacy of triple therapy is still not clear. The present study aimed to assess the effects of CYP2C19 gene polymorphisms on proton pump inhibitor (PPI), amoxicillin, and levofloxacin triple therapy for Helicobacter pylori (Hp) eradication. MATERIAL AND METHODS We randomly assigned 160 Hp-positive patients with chronic gastritis to 2 groups to receive either 20 mg bid omeprazole (OAL group, n=80) or 10 mg bid rabeprazole (RAL group, n=80), combined with 1000 mg bid amoxicillin and 500 mg qd levofloxacin...
June 3, 2017: Medical Science Monitor: International Medical Journal of Experimental and Clinical Research
https://www.readbyqxmd.com/read/28514401/-differentiation-therapy-for-non-acidic-gastroesophageal-reflux-disease
#7
N B Lishchuk, V I Simanenkov, S V Tikhonov
AIM: To investigate the clinical and pathogenetic features of the non-acidic types of gastroesophageal reflux disease (GERD) and to evaluate the impact of combined therapy versus monotherapy on the course of this disease. SUBJECTS AND METHODS: The investigation enrolled 62 patients with non-acidic GERD. The follow-up period was 6 weeks. The patients were divided into 2 groups: 1) weakly acidic gastroesophageal refluxes (GER); 2) weakly alkaline GER. Then each group was distributed, thus making up 4 groups: 1) 19 patients with weakly acidic GER who received monotherapy with rabeprazole 20 mg/day; 2) 21 patients with weakly acidic GER had combined therapy with rabeprazole 20 mg and itopride; 3) 8 patients with weakly alkaline GER who received ursodeoxycholic acid (UDCA) monotherapy; and 4) 14 patients with weakly alkaline GER who had combined therapy with UDCA and itopride, The clinical symptoms of the disease, the endoscopic pattern of the upper gastrointestinal tract (GIT) mucosa, histological changes in the esophageal and gastric mucosa, and the results of 24-hour impedance pH monitoring were assessed over time...
2017: Terapevticheskiĭ Arkhiv
https://www.readbyqxmd.com/read/28512024/repurposing-of-proton-pump-inhibitors-as-first-identified-small-molecule-inhibitors-of-endo-%C3%AE-n-acetylglucosaminidase-engase-for-the-treatment-of-ngly1-deficiency-a-rare-genetic-disease
#8
Yiling Bi, Matthew Might, Hariprasad Vankayalapati, Balagurunathan Kuberan
N-Glycanase deficiency, or NGLY1 deficiency, is an extremely rare human genetic disease. N-Glycanase, encoded by the gene NGLY1, is an important enzyme involved in protein deglycosylation of misfolded proteins. Deglycosylation of misfolded proteins precedes the endoplasmic reticulum (ER)-associated degradation (ERAD) process. NGLY1 patients produce little or no N-glycanase (Ngly1), and the symptoms include global developmental delay, frequent seizures, complex hyperkinetic movement disorder, difficulty in swallowing/aspiration, liver dysfunction, and a lack of tears...
July 1, 2017: Bioorganic & Medicinal Chemistry Letters
https://www.readbyqxmd.com/read/28502925/therapeutic-response-to-twice-daily-rabeprazole-on-health-related-quality-of-life-and-symptoms-in-patients-with-refractory-reflux-esophagitis-a-multicenter-observational-study
#9
Yoshikazu Kinoshita, Michio Hongo, Motoyasu Kusano, Yoshinori Furuhata, Hideaki Miyagishi, Satoshi Ikeuchi
Objective To investigate the effect of twice-daily rabeprazole doses on health-related quality of life in refractory patients. Methods and Patients Reflux esophagitis patients with an insufficient response to once-daily proton pump inhibitor therapy (Los Angeles Classification grade A-D) received rabeprazole 10 mg or 20 mg twice daily for 8 weeks. The health-related quality of life (SF-8™) and symptoms, using the Frequency Scale for the Symptoms of Gastroesophageal reflux disease, were evaluated before treatment and at weeks 4 and 8...
2017: Internal Medicine
https://www.readbyqxmd.com/read/28481007/the-influence-of-cyp2c19-polymorphisms-on-exacerbating-effect-of-rabeprazole-in-celecoxib-induced-small-bowel-injury
#10
Y Nuki, J Umeno, E Washio, Y Maehata, A Hirano, M Miyazaki, H Kobayashi, T Kitazono, T Matsumoto, M Esaki
BACKGROUND: Simultaneous use of proton pump inhibitors (PPIs) has been shown to increase the risk of nonsteroidal anti-inflammatory drug (NSAID)-induced small bowel injury. AIM: To investigate whether polymorphisms of the cytochrome P450 2C19 gene (CYP2C19), encoding a key metabolising enzyme for PPIs, are associated with small bowel injury induced by celecoxib in combination with the PPI rabeprazole. METHODS: Study participants included 55 healthy Japanese volunteers, who participated in the PPI-NSAID Kyushu University Study using video capsule endoscopy...
May 8, 2017: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/28430398/impact-of-acid-reducing-agents-on-the-pharmacokinetics-of-palbociclib-a-weak-base-with-ph-dependent-solubility-with-different-food-intake-conditions
#11
Wan Sun, Karen J Klamerus, Lisa M Yuhas, Sylvester Pawlak, Anna Plotka, Melissa O'Gorman, Leonid Kirkovsky, Maha Kosa, Diane Wang
Palbociclib free base capsule is a weak base drug with highly pH-dependent solubility. In vitro and in vivo studies evaluated the impact of acid-reducing agents on exposure of palbociclib and determined whether the impact, if any, can be mitigated by food. A drug-drug interaction study (study 1) was conducted first under fasted conditions and showed that coadministration of multiple doses of the proton-pump inhibitor rabeprazole substantially reduced palbociclib mean area under the concentration-time curve from time 0 to infinity and maximum observed plasma concentration by 62% and 80%, respectively...
April 21, 2017: Clinical Pharmacology in Drug Development
https://www.readbyqxmd.com/read/28366993/a-multicenter-randomized-trial-comparing-rabeprazole-and-itopride-in-patients-with-functional-dyspepsia-in-japan-the-nagoya-study
#12
Takeshi Kamiya, Michiko Shikano, Eiji Kubota, Tsutomu Mizoshita, Tsuneya Wada, Satoshi Tanida, Hiromi Kataoka, Hiroshi Adachi, Makoto Hirako, Noriaki Okuda, Takashi Joh
The aims of this study were to compare the therapeutic effects of a proton pump inhibitor (PPI), rabeprazole (RPZ), and a prokinetic agent, itopride (ITO), and to investigate the role of PPI in the treatment strategy for Japanese functional dyspepsia (FD) patients. We randomly assigned 134 patients diagnosed by Rome III criteria to 4 weeks treatment with RPZ 10 mg/day (n = 69) or ITO 150 mg/day (n = 65). Dyspeptic symptoms were evaluated using FD scores at baseline and after 1, 2 and 4 weeks of treatment...
March 2017: Journal of Clinical Biochemistry and Nutrition
https://www.readbyqxmd.com/read/28349044/vonoprazan-based-regimen-is-more-useful-than-ppi-based-one-as-a-first-line-helicobacter-pylori-eradication-a-randomized-controlled-trial
#13
Masafumi Maruyama, Naoki Tanaka, Daisuke Kubota, Masayuki Miyajima, Takefumi Kimura, Koujiro Tokutake, Ryujiro Imai, Toru Fujisawa, Hiromitsu Mori, Yoshiaki Matsuda, Shuichi Wada, Akira Horiuchi, Kendo Kiyosawa
Background. A new agent, potassium-competitive acid blocker vonoprazan (VPZ) has potent acid-inhibitory effects and may offer advantages over conventional H. pylori eradication therapies. We aimed to compare the eradication rate between VPZ-based treatment and PPI-based one. Methods. This randomized controlled trial was designed to assign 141 patients with H. pylori-positive gastritis to VPZ group (VPZ 20 mg, amoxicillin 750 mg, and clarithromycin 200 or 400 mg twice daily for 7 days) or PPI group (rabeprazole 20 mg or lansoprazole 30 mg, amoxicillin 750 mg, and clarithromycin 200 or 400 mg twice daily for 7 days)...
2017: Canadian Journal of Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/28340819/influence-of-proton-pump-inhibitors-on-mycophenolic-acid-pharmacokinetics-in-patients-with-renal-transplantation-and-the-relationship-with-cytochrome-2c19-gene-polymorphism
#14
H S Ciftci, M S Karadeniz, T Tefik, Y Caliskan, H Yazıcı, E Demir, A Turkmen, I Nane, F S Oguz, F Aydin
BACKGROUND: Most patients have serious digestive complications after renal transplantation. Therefore, it is important to protect gastrointestinal function to improve the survival rate of transplant patients. Proton pump inhibitors (PPIs) such as lansoprazole and rabeprazole are widely administered to renal transplant patients with mycophenolic acid (MPA) in the perioperative period. PPIs are metabolized by cytochrome (CYP) 2C19 enzymes. Mycophenolate sodium (MYF) and mycophenolate mofetil (MMF) have been used in immunosuppression...
April 2017: Transplantation Proceedings
https://www.readbyqxmd.com/read/28314392/combining-simplicity-with-cost-effectiveness-investigation-of-potential-counterfeit-of-proton-pump-inhibitors-through-simulated-formulations-using-thin-layer-chromatography
#15
Nejal M Bhatt, Vijay D Chavada, Mallika Sanyal, Pranav S Shrivastav
A simple, accurate and precise high-performance thin-layer chromatographic method has been developed and validated for the analysis of proton pump inhibitors (PPIs) and their co-formulated drugs, available as binary combination. Planar chromatographic separation was achieved using a single mobile phase comprising of toluene: iso-propranol: acetone: ammonia 5.0:2.3:2.5:0.2 (v/v/v/v) for the analysis of 14 analytes on aluminium-backed layer of silica gel 60 FG254. Densitometric determination of the separated spots was done at 290nm...
November 18, 2016: Journal of Chromatography. A
https://www.readbyqxmd.com/read/28294690/stereoselective-and-nonstereoselective-pharmacokinetics-of-rabeprazole-an-overview
#16
Ranjeet Prasad Dash, Rana Rais, Nuggehally R Srinivas
1. Proton pump inhibitors have been extensively used for the treatment of ailments due to increased gastric acid secretion such as peptic ulcers, gastroesophageal reflux disease, etc. 2. There are several approved drugs in the proton pump inhibitor class with the latest entries representing single enantiomer drugs of the previously approved racemic drugs. 3. Despite having a high degree of structural resemblance, rabeprazole, was shown to possess some unique differentiation from other drugs in the class. One of the key distinguishing features of rabeprazole was related to the lesser involvement of polymorphic metabolism in its pharmacokinetic disposition...
April 6, 2017: Xenobiotica; the Fate of Foreign Compounds in Biological Systems
https://www.readbyqxmd.com/read/28229392/determination-of-rabeprazole-enantiomers-in-commercial-tablets-using-immobilized-cellulose-based-stationary-phase
#17
Miri Kim, Su Kyung Yu, Quoc-Ky Truong, Xuan-Lan Mai, Hyun Kyu Chung, Jong-Seong Kang, Kyeong Ho Kim
Rabeprazole is one of the latest proton-pump inhibitors used for treatment of several gastrointestinal disorders. For therapeutic applications, rabeprazole has been administered as a mixture of R-(+) and S-(-) enantiomers. Owing to pharmacological and toxicological differences between stereoisomers, chiral recognition has now become an integral part of drug research and development. A simple and rapid liquid chromatographic method for enantioselective separation and determination of R-(+) and S-(-) enantiomers of rabeprazole in bulk drug and pharmaceutical formulations was developed...
March 2017: Archives of Pharmacal Research
https://www.readbyqxmd.com/read/28216974/comparative-study-vonoprazan-and-proton-pump-inhibitors-in-helicobacter-pylori-eradication-therapy
#18
Kouichi Sakurai, Hiroko Suda, Yumi Ido, Takayuki Takeichi, Ayako Okuda, Kiwamu Hasuda, Masahiro Hattori
AIM: To compare the effectiveness and safety of vonoprazan-based therapy with proton pump inhibitor (PPI)-based therapies to treat Helicobacter pylori (H. pylori). METHODS: We retrospectively analysed data from first-line (vonoprazan or PPI with 200 mg clarithromycin and 750 mg amoxicillin twice daily for 7 d) (n = 1353) and second-line (vonoprazan or PPI with 250 mg metronidazole and 750 mg amoxicillin twice daily for 7 d) (n = 261) eradication treatments for H...
January 28, 2017: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/28159656/influence-of-different-proton-pump-inhibitors-on-the-pharmacokinetics-of-voriconazole
#19
Fang Qi, Liqin Zhu, Na Li, Tingyue Ge, Gaoqi Xu, Shasha Liao
This study aimed to determine the influence of proton pump inhibitors (PPIs) on the pharmacokinetics of voriconazole and to characterise potential drug-drug interactions (DDIs) between voriconazole and various PPIs (omeprazole, esomeprazole, lansoprazole and rabeprazole). Using adjusted physicochemical data and the pharmacokinetic (PK) parameters of voriconazole and PPIs, physiologically based pharmacokinetic (PBPK) models were built and were verified in healthy subjects using GastroPlus(TM) to predict the plasma concentration-time profiles of voriconazole and PPIs...
April 2017: International Journal of Antimicrobial Agents
https://www.readbyqxmd.com/read/28045652/the-influence-of-changes-in-hospital-drug-formulary-on-the-prescription-of-proton-pump-inhibitors
#20
Raquel Vázquez-Mourelle, Eduardo Carracedo-Martínez
OBJECTIVE: To analyze the impact of introducing omeprazole in the drug formulary of the Hospital de Barbanza on prescriptions made in hospital and out-of-hospital (Outpatient Units and Primary Care) for all Proton Pump Inhibitors (PPIs). MATERIAL AND METHODS: A 36-month retrospective descriptive study in a level I hospital. The basic units of work are Dose-Population- Day in the outpatient setting, and the Defined Daily Dose/stays-day for hospitalized patients; the proportion of DDDs for omeprazole vs...
January 1, 2017: Farmacia Hospitalaria
keyword
keyword
34016
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"